Obesity May Increase Breast Cancer Risk in Women With BRCA Mutations

Obesity may lead to DNA damage in breast tissue in women who are carriers of BRCA1 or BRCA2 mutations, which could contribute to the development of breast cancer in an already high-risk group, according to a new, multi-institutional study by Weill Cornell Medicine scientists.

The study, published in the Feb. 22 issue of Science Translational Medicine, suggests that weight control and medications that affect body health could be an important part of protecting women with these transition genes, although more research is needed.

Christy A., M.D., lead author of the study, said obesity and physical health are known risk factors for breast cancer in the general population, "but whether modifiable factors contribute to breast cancer development in BRCA mutation carriers is rarely known." Brown. Emily Lippman and Janice Jacobs McCarthy are breast cancer researchers and assistant professors of medical biochemistry at Weill Cornell Medicine.

Preliminary results of biomedical studies on the effect of body weight on breast cancer development in non-obvious BRCA breast cancer carriers, according to the paper's lead author Dr. Bria Bhardwaj, who is currently a doctoral student at Cornell College of Medical Sciences. "Let us discuss the mechanical evidence from physicians about the potential benefit of left-sided intervention for breast cancer," he said.

They analyzed samples of noncancerous breast tissue from patients carrying BRCA1 or BRCA2 mutations who underwent breast augmentation surgery. Included women with body mass index (BMI) in rural areas less than 25 kg / m 2 and women with body mass index 25 or more, categories on them and more.

Through the use of contraceptives, there is research to improve body mass in women with BRCA mutations, which are positively associated with menstrual loss during the menstrual cycle. It is influenced by the nutritional hormones lipid and insulin, as well as the hormone estrogen, which is blamed for breast milk loss in many women with breast cancer.

In addition, there are scientists who can reduce the loss of core weight in breast milk by exposing it to metformin. One of the well-known drugs used to treat type 2 diabetes reduces the production of aromatase - an enzyme that plays a role in the biological synthesis of estrogen.

Metformin is an attractive educational method because of its negative language effects, so we can look at the possibility of using it in one of the dangerous areas, he said. Hello." In addition to genetic studies, researchers are analyzing BRCA1 mutations to determine if the excessive menstrual loss is linked to the development of carcinoid tumors. Scientists believe that the fat man of the lamp has a higher nutritional composition than that of the Nahla van. Behrouge Abghari said. In support of this study to understand the impact of lifestyle, lifestyle, and nutritional supplements on the progression of breast cancer in patients, Dr. Cal Brown. Changes or metformin in these patients. "While this research led to the emergence of BRCA1 and BRCA2 carriers," said Dr.Billion can be caused by cancer or other genetic factors.

Obesity may promote DNA damage in the breast tissue of women carrying BRCA1 or BRCA2 mutations, potentially contributing to the development of breast cancer in this already high-risk group, according to a new cross-institutional translational research effort led by Weill Cornell Medicine scientists.

The study, published in the Feb. 22 issue of Science Translational Medicine, suggests that weight management and medications that affect metabolic health could be an important part of preventive care for women with these genetic mutations, although more research is needed.

Obesity and poor metabolic health are known risk factors for breast cancer in the general population, "but whether these modifiable risk factors contribute to the development of breast cancer in BRCA mutation carriers has been largely unknown," said the study's lead author, Kristy A. Brown, Ph.D., the Emilie Lippmann and Janice Jacobs McCarthy Research Scholar in Breast Cancer and associate professor of biochemistry in medicine at Weill Cornell Medicine.

Obesity and breast cancer risk

Women who are considered overweight or obese-defined as having a BMI (body mass index) of 25 or more have a higher risk of developing hormone receptor-positive breast cancer than women who maintain a healthy weight, especially after menopause. Obesity can also increase the risk of breast cancer coming back (recurrence) in women who already have the disease.

This higher risk is due to the fact that fat cells produce estrogen; extra fat cells mean more estrogen in the body, and estrogen can promote the development and growth of hormone receptor-positive breast cancer.